CODX
Co-Diagnostics, Inc. NASDAQ Listed Jul 12, 2017$3.03
+1.68%
vs $2.98
Mkt Cap $3.4M
52w Low $1.26
3.9% of range
52w High $46.50
50d MA $3.43
200d MA $6.15
P/E (TTM)
—
EV/EBITDA
—
P/B
0.2x
Debt/Equity
0.1x
ROE
-227.3%
P/FCF
-0.1x
RSI (14)
23.80
ATR (14)
$0.59
Beta
1.43
50d MA
$3.43
200d MA
$6.15
Avg Volume
11.2M
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.
2401 S. Foothill Dr. · Salt Lake City, UT 84109 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | AMC | -3.60 | -16.35 | -354.2% | 1.86 | -7.5% | -12.9% | -4.9% | +0.0% | -7.8% | -2.1% | — |
| Nov 13, 2025 | AMC | -5.71 | -4.80 | +15.9% | 11.16 | -12.6% | -11.0% | -4.5% | +13.6% | -4.7% | -5.8% | — |
| Aug 14, 2025 | AMC | -0.25 | -0.23 | +8.0% | 7.95 | +27.2% | +10.9% | +8.8% | -9.4% | -2.8% | +8.9% | — |
| May 8, 2025 | AMC | -0.33 | -0.24 | +27.3% | 10.65 | -2.8% | -4.2% | +0.6% | +5.8% | -4.7% | -11.6% | — |
| Mar 27, 2025 | AMC | -0.34 | -0.36 | -5.9% | 11.76 | -3.1% | -18.4% | -3.1% | +5.8% | +9.1% | -9.8% | — |
| Nov 7, 2024 | AMC | -0.33 | -0.32 | +3.0% | 35.40 | -1.7% | -3.4% | +3.5% | -0.8% | -5.1% | -0.9% | — |
| Aug 8, 2024 | AMC | -0.34 | -0.25 | +26.5% | 30.60 | +4.9% | +9.8% | +2.7% | +1.7% | +3.4% | +2.5% | — |
| May 9, 2024 | AMC | -0.21 | -0.31 | -47.6% | 36.90 | -4.9% | -9.8% | -3.2% | +4.2% | +0.0% | +1.8% | — |
| Mar 14, 2024 | AMC | -0.20 | -0.50 | -150.0% | 35.70 | -5.0% | -10.1% | -0.9% | +3.8% | +0.0% | +6.4% | — |
| Nov 9, 2023 | AMC | -0.29 | -0.20 | +31.0% | 38.10 | -1.6% | -10.2% | +0.9% | +17.4% | +3.0% | +0.4% | — |
| Aug 10, 2023 | AMC | -0.24 | -0.31 | -29.2% | 36.30 | +3.3% | -4.1% | +12.1% | -6.9% | +1.7% | +1.6% | — |
| May 11, 2023 | AMC | -0.23 | -0.20 | +13.0% | 37.20 | +5.6% | +7.3% | +1.5% | +2.2% | -2.2% | -0.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 24 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $10.50 | $10.50 | +0.0% | -4.6% | -2.7% | +14.8% | -0.5% | -2.7% |
| Oct 28 | D. Boral Capital | Maintains | Buy → Buy | — | $37.80 | $27.00 | -28.6% | -54.8% | -13.3% | -5.3% | -1.7% | -12.2% |
| Oct 16 | D. Boral Capital | Maintains | Buy → Buy | — | $11.52 | $11.52 | +0.0% | -8.9% | -7.4% | +6.8% | -2.0% | -5.9% |
| Sep 19 | D. Boral Capital | Maintains | Buy → Buy | — | $12.90 | $13.17 | +2.1% | +1.9% | -4.3% | -4.5% | +3.5% | -9.4% |
| Sep 17 | D. Boral Capital | Maintains | Buy → Buy | — | $19.17 | $16.80 | -12.4% | -34.7% | +3.1% | +1.9% | -4.3% | -4.5% |
| Aug 15 | D. Boral Capital | Maintains | Buy → Buy | — | $7.95 | $10.11 | +27.2% | +10.9% | +8.8% | -9.4% | -2.8% | +8.9% |
| Mar 28 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $11.76 | $11.40 | -3.1% | -18.4% | -3.1% | +5.8% | +9.1% | -9.8% |
| Nov 11 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $34.20 | $33.90 | -0.9% | +3.5% | -0.8% | -5.1% | -0.9% | -3.6% |
| Aug 12 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $33.60 | $33.30 | -0.9% | +2.7% | +1.7% | +3.4% | +2.5% | +10.1% |
| Jun 17 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $47.70 | $46.80 | -1.9% | -8.8% | +5.5% | -5.2% | +1.4% | -5.4% |
| May 13 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $33.30 | $32.70 | -1.8% | -3.2% | +4.2% | +0.0% | +1.8% | -4.4% |
| Mar 15 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $35.70 | $33.90 | -5.0% | -10.1% | -0.9% | +3.8% | +0.0% | +6.4% |
| Dec 29 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $45.00 | $44.40 | -1.3% | -11.3% | +6.8% | -2.8% | +0.0% | -5.8% |
| Nov 13 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $34.20 | $33.90 | -0.9% | +0.9% | +17.4% | +3.0% | +0.4% | -1.1% |
| Aug 14 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $34.80 | $34.50 | -0.9% | +12.1% | -6.9% | +1.7% | +1.6% | -3.2% |
| May 15 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $39.90 | $41.40 | +3.8% | +1.5% | +2.2% | -2.2% | -0.7% | +3.0% |
| Mar 20 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $74.40 | $75.00 | +0.8% | -23.4% | +0.5% | -14.7% | -11.0% | -4.1% |
| Feb 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $90.90 | $90.90 | +0.0% | +2.0% | -2.6% | -4.7% | +0.7% | -0.7% |
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $109.50 | $106.80 | -2.5% | +0.5% | +0.3% | -2.7% | -1.1% | -4.0% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $134.40 | $130.50 | -2.9% | -3.8% | -4.6% | -6.1% | -2.6% | -1.3% |
| Aug 12 | Sidoti & Co. | Downgrade | Buy → Neutral | — | $193.80 | $129.90 | -33.0% | -30.7% | -3.8% | -4.6% | -6.1% | -2.6% |
| May 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $136.50 | $135.30 | -0.9% | +3.3% | +7.0% | -2.4% | +1.2% | +0.4% |
| Nov 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $259.50 | $273.00 | +5.2% | +7.6% | +4.0% | +0.9% | -1.8% | -5.2% |
| Mar 29 | Maxim Group | Downgrade | Buy → Hold | — | $291.00 | $287.10 | -1.3% | -12.2% | +0.2% | +11.7% | +0.2% | -1.6% |
| Mar 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $363.60 | $333.30 | -8.3% | -20.0% | -12.2% | +0.2% | +11.7% | +0.2% |
| Dec 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $319.80 | $313.20 | -2.1% | +3.4% | -3.2% | +1.8% | +2.2% | +3.2% |
| Nov 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $407.70 | $356.10 | -12.7% | -12.5% | -3.8% | -5.0% | +2.0% | -5.4% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $630.00 | $525.90 | -16.5% | -22.4% | -3.5% | -1.9% | -5.8% | -1.0% |
| May 20 | Maxim Group | Upgrade | Hold → Buy | — | $565.50 | $594.90 | +5.2% | -1.4% | -3.0% | +2.9% | -2.8% | -2.6% |
| May 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $512.10 | $531.00 | +3.7% | +2.2% | +8.0% | -1.4% | -3.0% | +2.9% |
| Mar 3 | Maxim Group | Downgrade | Buy → Hold | — | $534.30 | $431.70 | -19.2% | -19.4% | -16.4% | +18.7% | -9.5% | -23.7% |
| Feb 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $91.50 | $101.40 | +10.8% | +28.9% | +9.8% | +106.3% | +79.3% | -17.1% |
| Apr 9 | Maxim Group | Maintains | Buy → Buy | — | $32.10 | $33.60 | +4.7% | +0.9% | +0.0% | -0.7% | +0.7% | -1.4% |
| Mar 11 | H.C. Wainwright | Maintains | Buy → Buy | — | $36.00 | $36.90 | +2.5% | -0.8% | +0.0% | +0.8% | -4.2% | +0.0% |
No insider trades available.
8-K · 1.01
! Medium
Co-Diagnostics, Inc. -- 8-K 1.01: Equity Issuance
May 21
8-K · 2.02
!! High
Co-Diagnostics, Inc. -- 8-K 2.02: Earnings Results
Co-Diagnostics reported quarterly earnings results with non-GAAP financial measures disclosed in the accompanying press release exhibit.
May 14
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Co-Diagnostics reported 2025 full-year financial results, which investors should review for revenue growth, profitability trends, and cash position to assess the diagnostic company's commercial traction and sustainability.
Mar 31
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Codexis's dwindling cash position of $11.9 million raises concerns about runway and potential dilution from future financing, critical for a biotech company requiring sustained R&D investment.
Mar 10
Institutional (13F) — Top 4
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Private Advisory Group Llc | 1,181,633 | $199K | — | Dec 2025 |
| 2 | Jane Street Group, Llc | 240,919 | $41K | Added | Dec 2025 |
| 3 | Morgan Stanley | 4,400 | $742 | Reduced | Dec 2025 |
| 4 | Advocate Investing Services Llc | 78 | $13 | New | Dec 2025 |
Mutual Funds / ETFs (N-PORT) — Top 0
All ↗
No N-PORT holders found.
Valuation
Market Cap
$3.4M
Enterprise Value
-$7.3M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.03x
P/B
0.20x
P/S
5.61x
P/FCF
-0.13x
EV/EBITDA
—
Shares Out
1.3M
Financials (TTM)
Revenue
$718K
Net Income
-$48.5M
EBITDA
-$49.0M
Free Cash Flow
-$29.8M
Op Cash Flow
-$29.1M
EPS Basic
$-35.25
EPS Diluted
$-32.26
EPS Forward
$-12.15
Gross Margin
9.5%
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$24.7M
Total Liab.
$4.1M
Total Equity
$20.6M
Cash
$11.9M
LT Debt
$574K
Book Value/Sh
$15.51
Debt/Equity
0.06x
Current Ratio
3.87
Quick Ratio
3.59
Returns & Growth
ROE
-227.3%
ROA
-189.5%
ROIC
-138.3%
Rev Growth YoY
-84.1%
EPS Growth YoY
+5.2%
Price Returns
2W
-30.5%
1M
-65.1%
3M
+75.3%
6M
-45.1%
12M
-64.5%
Technicals
52W High
$46.50
52W Low
$1.26
50d MA
$3.43
200d MA
$6.15
RSI (14)
23.80
ATR (14)
$0.59
Beta
1.43
Avg Volume
11.2M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$180.00
High
$180.00
Low
$180.00
Median
$180.00
Data updated apr 25, 2026 2:28am
· Source: financialmodelingprep.com